SCHEMBL7678249

SCHEMBL7678249

CCOC(=O)C(C)c1ccc(C(=O)c2ccc(Cl)cc2)n1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.44
ABCB11 O95342 1/20 0.44
GPR119 Q8TDV5 1/20 0.44
CXCL8 P10145 1/20 0.42
AKR1B1 P15121 1/20 0.42
PTGS1 P23219 1/20 0.42
GLO1 Q04760 1/20 0.42
HTT P42858 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
HRH3 Q9Y5N1 6/20 0.41
LMNA P02545 3/20 0.39
KMT2A Q03164 3/20 0.39
ALDH1A1 P00352 2/20 0.39
TSHR P16473 2/20 0.39
CYP1A2 P05177 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
MEN1 O00255 2/20 0.39
ADORA3 P0DMS8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7682420 0.86 PTGS2 (0.41) PTGS2ABCB11CXCL8AKR1B1PTGS1
SCHEMBL7678015 0.84 HTT (0.48) PTGS2ABCB11CXCL8AKR1B1PTGS1
SCHEMBL11814670 0.82 HTT (0.47) PTGS2ABCB11CXCL8AKR1B1PTGS1
SCHEMBL11811925 0.81 TSHR (0.45) PTGS2ABCB11CXCL8AKR1B1PTGS1
SCHEMBL7678100 0.81 ABCB11 (0.58) PTGS2ABCB11GPR119HTTSMN1; SMN2
SCHEMBL11822151 0.79 HTT (0.43) PTGS2ABCB11CXCL8AKR1B1PTGS1
SCHEMBL7676873 0.77 HTT (0.44) PTGS2ABCB11CXCL8AKR1B1PTGS1
SCHEMBL7678547 0.75 PTGS2 (0.56) PTGS2ABCB11CXCL8AKR1B1PTGS1
SCHEMBL7674823 0.75 HTT (0.44) PTGS2ABCB11CXCL8AKR1B1PTGS1
SCHEMBL11813514 0.74 HRH3 (0.46) CXCL8HTTSMN1; SMN2HRH3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455703-B2 ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION CELL PATHWAYS, INC. 2002-09-24 US disclosed
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia OSI PHARMACEUTICALS, INC. 2001-12-13 US disclosed
US-6160003-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS, INC. (US) 2000-12-12 US disclosed
US-5939417-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS INC (US) 1999-08-17 US disclosed
US-5721347-A Esters and amides of substituted pyrrole acetic acids CELL PATHWAYS, INC. (US) 1998-02-24 US disclosed
EP-0485157-A2 Esters and amides of substituted pyrrole acetic acids FGN, INC. (US) 1992-05-13 EP disclosed
US-3952012-A MULTISTAGE MCNEIL LABORATORIES, INCORPORATED (US) 1976-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia MALT1, VHL, CDKN1A PTGS2 887/4885ABCB11 2317/4885GPR119 3311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.